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Hematopoietic stem cells (HSCs) and an earlier wave
of definitive erythroid/myeloid progenitors (EMPs)
differentiate from hemogenic endothelial cells in the
conceptus. EMPs can be generated in vitro from
embryonic or induced pluripotent stem cells, but
efforts to produce HSCs have largely failed. The
formation of both EMPs and HSCs requires the tran-
scription factor Runx1 and its non-DNA binding
partner core binding factor b (CBFb). Here we show
that the requirements for CBFb in EMP and HSC
formation in the conceptus are temporally and
spatially distinct. Panendothelial expression of
CBFb in Tek-expressing cells was sufficient for
EMP formation, but was not adequate for HSC
formation. Expression of CBFb in Ly6a-expressing
cells, on the other hand, was sufficient for HSC, but
not EMP, formation. The data indicate that EMPs
and HSCs differentiate from distinct populations of
hemogenic endothelial cells, with Ly6a expression
specifically marking the HSC-generating hemogenic
endothelium.
INTRODUCTION
Hematopoietic stem cells (HSCs), which reside in the bone
marrow of adult mammals, differentiate from a small population
of endothelial cells in the conceptus, referred to as ‘‘hemogenic
endothelium’’ (Bertrand et al., 2010; Boisset et al., 2010; Chen
et al., 2009; Jaffredo et al., 2005; Kissa et al., 2008; Zovein
et al., 2008). Before HSCs appear, committed erythroid/myeloid
progenitors (EMPs) emerge in the yolk sac, also from hemogenic
endothelium. HSCs capable of repopulating adult mice are first
detected at 10.5 days postcoitis (dpc; 35 somite pair stage,
or 35s) in the dorsal aorta and vitelline and umbilical arteries,
and at 11.0–11.5 dpc in the fetal liver, yolk sac, and placenta
(de Bruijn et al., 2000; Gekas et al., 2005; Medvinsky et al.,
1996;Mu¨ller et al., 1994; Ottersbach and Dzierzak, 2005). Hemo-Celgenic endothelium is located in all sites of EMP and HSC emer-
gence including the ventral aspect of the dorsal aorta, vitelline
and umbilical arteries, yolk sac, and placenta. The process by
which blood forms from hemogenic endothelium has been
most well studied in the dorsal aorta and in ESC cultures, and
involves an endothelial to hematopoietic cell transition during
which individual cells round up and detach from the endothelial
layer (Bertrand et al., 2010; Boisset et al., 2010; Kissa andHerbo-
mel, 2010; Eilken et al., 2009; Lancrin et al., 2009). This rounding
up (budding) process can be toward the lumen of an artery
(prominent in mammals and birds) (Jaffredo et al., 2005), where
many newly formed hematopoietic cells collect in clusters that
are presumably released into the circulation. Alternatively, the
budding can occur in the opposite direction, into the subaortic
mesenchyme, after which single hematopoietic cells enter the
circulation through the axial vein by intravasation (zebrafish)
(Bertrand et al., 2010; Kissa et al., 2008).
Hemogenic endothelium is distinguished from all other endo-
thelial cells by the presence of a transcription factor called
Runx1 (Northetal., 1999).Runx1 isexpressed inhemogenicendo-
thelial cells in early somite pair stage conceptuses prior to the
formation of clusters, in the clusters themselves, and in all func-
tional EMPs and HSCs (North et al., 1999, 2002). Fetuses lacking
Runx1 have no EMPs, HSCs, or intra-arterial clusters (Cai et al.,
2000; North et al., 1999, 2002; Okuda et al., 1996; Wang et al.,
1996a). In zebrafish Runx1 morphants, most aortic endothelial
cells did not attempt the endothelial to hematopoietic cell transi-
tion, and those that did self-destructed by what appeared to be
an apoptotic-like process (Kissa and Herbomel, 2010).
We showed that deletion of a conditional Runx1 allele in endo-
thelial cells with Cre recombinase driven from Cdh5 (encoding
vascular endothelial cadherin) or Tek (encoding the angiopoietin
receptor Tie2) regulatory sequences blocked EMP, HSC, and
intra-arterial cluster formation, indicating that Runx1 is required
in the hemogenic endothelium for the endothelial to hematopoi-
etic cell transition (Chen et al., 2009; Li et al., 2006). A comple-
mentary study (Liakhovitskaia et al., 2009) demonstrated that
restoring Runx1 function in endothelial cells in Runx1-deficient
embryos rescued both EMP and HSC formation. The latter
experiment involved reactivating an inactive Runx1 allele with
Tek-Cre, allowing Runx1 to be appropriately expressed from
its endogenous locus in Tek+ hemogenic endothelial cells, andl Stem Cell 9, 541–552, December 2, 2011 ª2011 Elsevier Inc. 541
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development.
Runx1 function during hematopoiesis requires the activity of
a non-DNA binding subunit, core binding factor b (CBFb), which
allosterically regulates DNA binding by Runx1 (Sasaki et al.,
1996; Wang et al., 1996b; Yan et al., 2004). Fetuses lacking
CBFb had dramatically impaired hematopoiesis, although
some residual EMPs remained (Wang et al., 1996b). Fetuses
with only 15% of wild-type CBFb levels had functional EMPs
and HSCs (Talebian et al., 2007); thus, very low levels of CBFb
are needed to support EMP and HSC formation. We previously
showed that restoring CBFb expression in Tek+ cells would
rescue EMP formation in the fetus (Miller et al., 2002). Our rescue
strategy was different from that employed by Liakhovitskaia et al.
(2009), in that we expressed CBFb (fused to the green fluores-
cent protein, GFP/CBFb) as a transgene from Tek regulatory
sequences in CBFb-deficient fetuses (Miller et al., 2002).
Although GFP/CBFb was detected in endothelial cells, its level
in hematopoietic cells, including Sca1+ or c-Kit+ fetal liver cells,
was low (Miller et al., 2002). Fetal liver EMPs were rescued by
the Tek-GFP/Cbfb transgene, but GFP/CBFbwas not expressed
at later stages of blood cell differentiation, and consequently
the terminal differentiation of all hematopoietic cells, with the
exception of erythrocytes, was impaired.
Another marker of endothelial cells in hematopoietic sites
is the HSC cell surface protein Sca1, which is encoded by
the Ly6a gene (de Bruijn et al., 2002; Ottersbach and Dzierzak,
2005). Surface Sca1 is found on only 50% of aorta/gonad/
mesonephros (AGM) HSCs (de Bruijn et al., 2002; North et al.,
2002). However, expression of GFP from the Ly6a regulatory
sequences marked all functional HSCs in the dorsal aorta, fetal
liver, and placenta (de Bruijn et al., 2002; Ottersbach and Dzier-
zak, 2005). GFP+ cells were found among the endothelial cells of
the dorsal aorta, vitelline and umbilical arteries, and placenta, but
not all endothelial cells in these sites were GFP+. A recently
published live imaging study that utilized the Ly6a-GFP trans-
gene tracked the budding of GFP+ hematopoietic cells into the
lumen of the dorsal aorta in slice cultures from 10.5 dpc fetuses
(Boisset et al., 2010).
Here we show that a GFP/CBFb fusion protein expressed from
the Tek regulatory sequences in CBFb-deficientmice is sufficient
to restore EMPs formation, but insufficient for HSC formation.
Conversely, expressing GFP/CBFb from Ly6a regulatory
sequences will rescue HSC formation, but not EMP formation.
These data indicate that EMP and HSC formation can be
uncoupled, and that Ly6a expression specifically marks a subset
of hemogenic endothelial cells that are destined to produce
HSCs.
RESULTS
Expression of GFP/CBFb from the Tek Regulatory
Sequences Cells Fails to Rescue HSCs
in Cbfb–/– Fetuses
Wepreviously showed that aGFP/CBFb fusion protein, when ex-
pressed from a Tek-driven transgene, could rescue EMPs in the
fetal liver of 12.5 dpc Cbfb/ fetuses (Miller et al., 2002). The
number of EMPs was lower than in wild-type fetuses, but was
sufficient for Cbfb/;Tek-GFP/Cbfb conceptuses to complete542 Cell Stem Cell 9, 541–552, December 2, 2011 ª2011 Elsevier Incgestation (lethality was at postnatal day 1). Cbfb/ fetuses, on
the other hand, died at midgestation with almost no EMPs (Miller
et al., 2002; Wang et al., 1996b). We also showed that 17.5 dpc
Cbfb/;Tek-GFP/Cbfb fetuses contained both B and T lympho-
cytes, but in reduced numbers (Miller et al., 2002). We assessed
the B and T lymphoid potential of 14.5 dpc Cbfb/;Tek-GFP/
Cbfb fetuses by isolating fetal liver lymphoid progenitors
(Linc-Kit+Flt3+) and coculturing them with either OP9 stromal
cells or Notch-ligand-expressing OP9-DL4 stromal cells.
Cbfb/;Tek-GFP/Cbfb progenitors yielded small numbers of
CD19+B220+ B cells in OP9 cultures, and Thy1+CD25+ T cells
in OP9-DL4 cultures (Figure 1A). Limit dilution analysis deter-
mined thatCbfb/;Tek-GFP/Cbfb fetal livers contained approx-
imately 30-fold fewer B cell progenitors and 15-fold fewer T cell
progenitors within the Linc-Kit+Flt3+ population as com-
pared with Cbfb+/+;Tek-GFP/Cbfb (heretofore referred to as
Tek-GFP/Cbfb) fetal livers (Figure 1B). Methylcellulose colony
assays using unfractionated fetal liver cells similarly showed
that Cbfb/;Tek-GFP/Cbfb fetuses contained 11-fold fewer B
progenitors than Tek-GFP/Cbfb fetuses (not shown). We trans-
planted 14.5 dpc fetal liver cells from Cbfb/;Tek-GFP/Cbfb
conceptuses into irradiated adult mice to assess HSCs and
observed no donor contribution to the peripheral blood or
bone marrow (Figure 1C). Thus fetal liver lymphoid progenitors
and HSCs are poorly rescued by the Tek-GFP/Cbfb transgene.
Examination of the fetal liver revealed that there were lower
numbers of cells overall, and even fewer LinSca1+c-Kit+ (LSK)
cells (Figure 1D). We previously showed by western blot that
the amount of GFP/CBFb fusion protein produced from the
Tek-GFP/Cbfb transgene in embryonic skin was equivalent to
that of endogenous CBFb, but was undetectable in CD45+ or
c-Kit+ fetal liver cells (Miller et al., 2002).We extended those find-
ings by examining GFP/CBFb levels in phenotypic HSCs and
LT-HSCs by FACS. Fewer than 10% of phenotypic HSCs (LSK)
and LT-HSCs (CD48 CD150+ LSK) in the liver of Tek-GFP/
Cbfb fetuses were GFP/CBFb+ (Figure 1E). Thus, GFP/CBFb
expression from the Tek-GFP/Cbfb transgene is not sustained
in the majority of newly formed HSCs, which, as discussed later,
may contribute to its failure to rescue HSC formation in Cbfb/
fetuses.
Expression of GFP/CBFb from the Ly6a Regulatory
Sequences Fails to Rescue EMPs
We next tried to rescue EMP and HSC formation in Cbfb/
fetuses using a Ly6a-driven transgene. Three Ly6a-GFP/Cbfb
founders were generated, all of which produced GFP/CBFb at
levels similar to that of endogenous CBFb in unfractionated adult
bone marrow cells (Figure 2A). Essentially 100% of adult bone
marrow LSK and CD48 CD150+ LSK cells in Ly6a-GFP/Cbfb
mice were GFP/CBFb+, although the mean fluorescence inten-
sity differed in independent founder lines (line A > B > C) (Fig-
ure 2B). Expression from the Ly6a-GFP/Cbfb transgene at 11.5
dpc mirrored that described for Ly6a-GFP (de Bruijn et al.,
2002; Ottersbach and Dzierzak, 2005). GFP/CBFb+ cells were
present in the placental and umbilical vasculature, vitelline
artery, and AGM region (including the mesonephric tubules
and Wolffian/Mullerian ducts) (Figure 2C). Fetal liver CD48
CD150+ LSK cells were 80% GFP/CBFb+ in the strongest-
expressing Ly6a-GFP/Cbfb line (Figure 2D)..
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Figure 1. Expression of GFP/CBFb from the Tek Regulatory Sequences Poorly Rescues Lymphoid Progenitor and HSC Formation
(A) Fetal liver progenitors (LinKit+Flt3+) were sorted from 14.5 dpc embryos and plated on OP9 or OP9-DL4 stromal cells. Numbers of cells plated were 400 and
200 Tek-GFP/Cbfb on OP9 and OP9-DL1, respectively; and 2,000Cbfb/; Tek-GFP/Cbfb on both OP9 and OP9-DL4. OP9 cultures contained 5 ng/ml Flt3L and
10 ng/ml IL-7. OP9-DL4 cultures contained 5 ng/ml Flt3L and 1 ng/ml IL-7. Cells were analyzed for the expression of lymphoid markers 7 days later.
(B) Limit dilution analysis of fetal liver progenitors cultured as described above.
(C) Percent and number of recipients containingR5%donor-derived blood 16weeks following transplantationwith 23 105, 53 105, or 13 106 14.5 dpc fetal liver
cells from wild-type (+/+), Cbfb/ (/), and Cbfb/; Tek-GFP/Cbfb (/;Tek) conceptuses.
(D) Representative scatter plots of 13.5 dpc fetal liver HSCs (LSK cells). Total number of fetal liver and LSK cells at 13.5 dpc are graphed below. Data are compiled
from two to five fetuses. Error bars represent standard error of the mean (SEM).
(E) Representative histograms showing GFP/CBFb expression in the LSK and LT-HSC populations of 13.5 dpc Tek-GFP/Cbfb fetal livers. The two green traces
and percentages in the histograms represent two independent fetuses.
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HSC-Producing Hemogenic Endothelial CellsThe three independent Ly6a-GFP/Cbfb transgenes were
crossed onto the Cbfb/ background. Surprisingly,
Cbfb/;Ly6a-GFP/Cbfb conceptuses died in utero at the
same time as Cbfb/ conceptuses (Figure S1 available online).
Cbfb/;Ly6a-GFP/Cbfb fetal livers were pale, suggesting that
colonization by yolk sac EMPs had not occurred. Hematopoietic
assays were performed to examine EMPs in Cbfb/;Tek-GFP/CelCbfb versus Cbfb/;Ly6a-GFP/Cbfb versus Cbfb/;Tek-
GFP/Cbfb;Ly6a-GFP/Cbfb conceptuses (Figure 3). Two-way
comparisons using Student’s t test revealed significantly
higher numbers of EMPs in Cbfb/;Tek-GFP/Cbfb versus
Cbfb/ conceptuses (fetal liver and yolk sac), and in
Cbfb/;Tek-GFP/Cbfb versus Cbfb/;Ly6a-GFP/Cbfb
conceptuses (fetal liver and placenta) at 11.5 dpc (Figure 3).l Stem Cell 9, 541–552, December 2, 2011 ª2011 Elsevier Inc. 543
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Figure 2. Expression of GFP/CBFb in Endothelial Cells and Hematopoietic Cells from the Ly6a-GFP/Cbfb Transgene
(A) Western blot analysis of whole bonemarrow fromwild-type, Ly6a-GFP, and three independent Ly6a-GFP/Cbfb lines using amonoclonal antibody recognizing
CBFb. Endogenous CBFb and the GFP/CBFb fusion protein are indicated. Whole cell lysates from 2 3 105 cells were loaded.
(B) Representative histograms showing GFP/CBFb expression in the LSK and LT-HSC populations in the bone marrow (BM) of thee independent lines of adult
Ly6a-GFP/Cbfb mice.
(C) (Left) Whole-mount immunofluorescence of an 11.5 dpc Ly6a-GFP/Cbfb conceptus. The fetus is outlined with a dashed white line. Pl, placenta; UA, umbilical
artery. (Right) An isolated AGM region with expression in the dorsal aorta (DA), vitelline artery (VA), UA, mesonephric tubules (MT), and Wolffian/Mullerian ducts
(W/M), identical to that reported for the Ly6a-GFP transgene (de Bruijn et al., 2002).
(D) Representative histograms showing GFP/CBFb expression in the majority of phenotypic LT-HSCs in a 13.5 dpc Ly6a-GFP/Cbfb fetal liver (FL, Line A).
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HSC-Producing Hemogenic Endothelial CellsAlthough the number of EMPs in Cbfb/;Tek-GFP/Cbfb fetal
livers was initially low, it increased considerably over the next
few days, and by 14.5 dpc EMPswere only 33% fewer in number
than in Tek-GFP/Cbfb conceptuses (Figure 3). Cbfb/ fetuses
carrying both the Tek-GFP/Cbfb and Ly6a-GFP/Cbfb trans-
genes had significantly higher numbers of EMPs in all tissues
at 11.5 dpc (Figure 3), indicating that the two transgenes comple-
mented each other. In summary, the Tek-GFP/Cbfb transgene
rescues EMPs and fetal viability significantly better than the
Ly6a-GFP/Cbfb transgene. We conclude that the Ly6a-GFP/
Cbfb transgene is not expressed at the correct time, or in the
correct cells, to adequately restore EMP formation and rescue
the viability of Cbfb/ fetuses.
Expression of GFP/CBFb from the Ly6a Regulatory
Sequences Rescues HSCs
Since most Cbfb/;Ly6a-GFP/Cbfb fetuses died by 13.5 dpc,
we assayed hematopoietic tissues at 11.5 dpc for the presence
of HSCs. Quite surprisingly, the Ly6a-GFP/Cbfb transgene
restored HSC formation in all hematopoietic tissues except for
the AGM region and vitelline and umbilical arteries (A+U+V)
(Figure 4A). High-level reconstitution by Cbfb/;Ly6a-GFP/
Cbfb HSCs was observed in multiple recipients (6 out of 17),
with contribution to both lymphoid and myeloid lineage cells544 Cell Stem Cell 9, 541–552, December 2, 2011 ª2011 Elsevier Inc(Figure 4B). Cbfb/ fetuses expressing both the Tek-GFP/
Cbfb and Ly6a-GFP/Cbfb transgenes had HSCs in all hemato-
poietic sites including the A+U+V (Figure 4A); thus, the two trans-
genes complemented each other in HSC formation. We
observed reconstitution of only one recipient by Cbfb/;Tek-
GFP/Cbfb HSCs that had received 0.9 embryo equivalents of
placental cells. These results confirm previous data showing
that HSCs are associated with endothelium marked by Ly6a
transgene expression (de Bruijn et al., 2002; Ottersbach and
Dzierzak, 2005), and further show that CBFb function in Ly6a-
expressing cells is sufficient for HSC, but not for EMP, formation.
Comparison of Tek-GFP/Cbfb and Ly6a-GFP/Cbfb
Expression
Since the Tek-driven transgene selectively rescued EMP forma-
tion, and the Ly6a-driven transgene restored only HSC forma-
tion, comparison of their expression patterns during embryonic
development should reveal when and in what cells CBFb is
required. We first considered why the Ly6a-GFP/Cbfb transgene
failed to rescue EMP formation. EMPs are detected in the yolk
sac beginning at 8.25 dpc (2–6s) (Palis et al., 1999) as clusters
of CD41bright cells at the border between the yolk sac blood
islands and the capillary bed leading to the embryo proper (Fer-
kowicz et al., 2003). No GFP/CBFb+ cells were found anywhere.
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Figure 3. EMPs in Cbfb–/– Conceptuses Are
Rescued upon Expression of GFP/CBFb
from the Tek-Driven, but Not the Ly6a-
Driven, Transgene
Shown are the numbers of hematopoietic
progenitors (colonies) per embryo equivalent (ee)
in four hematopoietic tissues: fetal liver, yolk sac,
AGM region combined with umbilical and vitelline
arteries (A+U+V), and placenta. Numbers are
compiled from 3–14 11.5 or 14.5 dpc conceptuses
per genotype. p values in boxes indicate signifi-
cant differences in total progenitor numbers in
Cbfb/ conceptuses (/, indicated by #) versus
Cbfb/ conceptuses carrying transgenes as
determined by one-way ANOVA. Error bars
represent SEM. Asterisks indicate significant
differences compared with / (p < 0.01) ac-
cording to Dunnett’s Multiple Comparison test.
Differences between Cbfb/, Cbfb/; Tek-GFP/
Cbfb (/; Tek) and Cbfb/; Ly6a-GFP/Cbfb
(/; Ly6a) were determined by unpaired two-
tailed Student’s t test. Cbfb/; Tek-GFP/Cbfb;
Ly6a-GFP/Cbfb is /; Tek+Ly6a. See also Fig-
ure S1.
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HSC-Producing Hemogenic Endothelial Cellsin Ly6a-GFP/Cbfb conceptuses at this time or in slightly older
10–11s conceptuses (Figure 5B). In contrast, the Tek-GFP/
Cbfb transgene, which rescued EMP formation, was highly
expressed in endothelial cells throughout 6–7s conceptuses,
the yolk sac vascular plexus, dorsal aortae, heart (endocardial
tube), allantois, and placenta (Figure 5A). Therefore the Tek-
GFP/Cbfb transgene was expressed in endothelial cells at the
time of EMP emergence in the yolk sac, but the Ly6a-GFP/
Cbfb transgene was not.
The fact that the Ly6a-GFP/Cbfb transgene rescued HSC
formation means that the onset of its expression could define
the earliest time point at which CBFb is required to specify
HSCs. Initiation of Ly6a-GFP/Cbfb transgene expression was
found in a subset of endothelial cells between 11s and 16s (9
dpc) (Figure 5D and Movie S1, available online). These included
endothelial cells in the dorsal aorta, the vitelline vasculature,
placenta, and the yolk sac vascular plexus primarily (although
not exclusively) at the caudal end of the conceptus. A half day
later (24s, 9.5 dpc), expression of Ly6a-GFP/Cbfb in the yolk
sac is confined to the major vitelline vessels (Figure S2 and
Movie S2). The appearance of Ly6a-GFP/Cbfb-expressing
endothelial cells precedes the presence of both yolk sac HSCs
capable of repopulating busulfan-conditioned neonatal recipi-
ents (13–20s) (Yoder et al., 1997) and AGM HSCs that can repo-
pulate adult irradiated recipients (>34s, 10.5 dpc) (Medvinsky
andDzierzak, 1996;Mu¨ller et al., 1994). Thus, CBFb is not neces-
sary for HSC formation until, at the very earliest, the 11–16s
stage. Further, the inability of the Ly6a-GFP/Cbfb transgene to
rescue EMP formation indicates that CBFb is required beforeCell Stem Cell 9, 541–552, Dthe 16s stage for EMP formation, and/or
that EMPs develop from Ly6a endothe-
lial cells.
Transgene expression was also exam-
ined at 10.5 dpc, when adult repopulating
HSCs appear. Ly6a-GFP/Cbfb expres-sion was intense in a subset of endothelial cells located in the
regions of HSC emergence, including the dorsal aorta and umbil-
ical and vitelline vasculature (Figure 6B and Movie S3). GFP/
CBFb+ cells in the yolk sac were mostly confined to the larger
vitelline vessels, as reported previously (Figure 6D) (de Bruijn
et al., 2002). In contrast to the Ly6a-driven transgene, which
marks a relatively restricted population of endothelial cells that
include a subset of hemogenic endothelial cells, the Tek-GFP/
Cbfb transgene was expressed throughout the vasculature of
the 10.5 dpc conceptus, although not uniformly in all endothelial
cells (Figures 6A and 6E). Tek-GFP/Cbfb was also expressed in
the yolk sac at 10.5 dpc in the vascular plexus as well as in the
larger vitelline vessels (Figure 6C). FACS analysis of A+U+V of
11.5 dpc Tek-GFP/Cbfb and Ly6a-GFP/Cbfb conceptuses indi-
cated that 18.2% and 20.2%, respectively, of CD144+ CD45
endothelial cells were GFP/CBFb+ (Figure S3C). Fetuses ex-
pressing both transgenes had a significantly higher percentage
of endothelial cells that were GFP/CBFb+ (33.5%), suggesting
that the two transgenes were expressed in partially nonoverlap-
ping endothelial cell populations. Thus, differences in the per-
centage of endothelial cells expressing Tek-GFP/Cbfb versus
Ly6a-GFP/Cbfb do not underlie the distinct abilities of these
two transgenes to rescue EMPs and HSCs. The failure of the
Tek-GFP/Cbfb transgene to rescue HSCs must either be due
to suboptimal expression in endothelial cells that give rise to
HSCs, or premature extinction of its expression in HSCs.
We examined whether other HSC/endothelial markers could
be used as surrogates for Ly6a-driven transgenes. Endothelial
specific adhesion molecule (ESAM) is expressed on fetal liverecember 2, 2011 ª2011 Elsevier Inc. 545
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Figure 4. Expression of GFP/CBFb from the Ly6a Regulatory
Sequences Rescues HSCs in Cbfb–/– Conceptuses
(A) Repopulation by 0.9 ee of 11.5 dpc cells from conceptuses of the in-
dicated genotypes at 4 months posttransplant. Percent donor-derived
blood is plotted; each dot is an individual transplant recipient. Error bars
represent SEM.
(B) Multilineage engraftment by donor-derived wild-type and Cbfb/; Ly6a-
GFP/Cbfb HSCs in a recipient of placenta cells.
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HSC-Producing Hemogenic Endothelial CellsHSCs, and in the AGM region on c-Kit+ cells and lymphoid
progenitors (Yokota et al., 2009). The vast majority (>95%) of
GFP/CBFb+ hematopoietic and endothelial cells in the 10.5
dpc A+U+V were ESAM+, demonstrating that cell-surface
ESAM marks HSCs and HSC-producing endothelium (Figures
7A and 7B). However, fewer than 15% of vascular endothelial
cadherin (CD144+) ESAM+ endothelial or hematopoietic cells
were GFP/CBFb+. Therefore ESAM cannot substitute for Ly6a-
driven transgenes to enrich for HSCs or HSC-producing endo-
thelium. We found the same to be true for endoglin (CD105)546 Cell Stem Cell 9, 541–552, December 2, 2011 ª2011 Elsevier Incand Tek; i.e., most GFP/CBFb+ hematopoietic or endothelial
cells in the A+U+V expressed these markers, but fewer than
15% of cells expressing these markers were GFP/CBFb+
(Figures 7A and 7C). The percentage of Flk1+ cells is relatively
low compared with ESAM, CD105, and Tek, and less useful for
isolation or analysis of HSCs and HSC-producing hemogenic
endothelium (Figures 7A and 7C). We obtained similar results
with Ly6a-GFP embryos (data not shown), indicating that the
Ly6a regulatory sequences faithfully reproduce this expression
pattern in independently derived transgenic mice. In summary,
Ly6a-driven transgenes mark a subset of endothelial cells
(CD31+, CD144+, ESAM+, CD105+, Tek+) and hematopoietic
cells (c-Kit+ and presumably Runx1+), and thus enrich for
HSCs and HSC-producing endothelium. Ly6a transgene expres-
sion does not, however, remain restricted to this small popula-
tion of endothelial cells throughout development; at later gesta-
tional ages its expression expands to other cell types, including
some veins, epithelial cells of the metanephric kidney, endothe-
lial and other cells in the fetal liver, lungmacrophages (Figure S4),
and a variety of other adult tissues (Holmes and Stanford, 2007;
Ma et al., 2002b).
Ly6a Expression Is Not Regulated by CBFb
The restricted endothelial expression of the Ly6a transgene in
sites of HSC emergence suggested it might be a target of
Runx1-CBFb. However, we found no evidence for this. There
were GFP/CBFb+ cells in the umbilical and placental vasculature
in both Ly6a-GFP/Cbfb and Cbfb/; Ly6a-GFP/Cbfb 11.5 dpc
conceptuses, and a similar percentage of Sca1+ GFP/CBFb+
cells in the vasculature (A+U+V, Figures S5A and S5B). The
percentage of GFP/CBFb+ endothelial (CD45CD144+) cells in
the A+U+V was also equivalent (Figures S5C and S5D), and
GFP/CBFb+ CD31+ cells were clearly visible in the endothelial
layer of the dorsal aorta of 10.5 dpc Cbfb/; Ly6a-GFP/Cbfb
fetuses (Figure S5E). Thus Runx1 and Ly6a are regulated inde-
pendently. Runx1 expression marks all hemogenic endothelium
that gives rise to EMPs and HSCs. Ly6a expression, on the other
hand, marks the subset of hemogenic endothelium that gives
rise to HSCs (Figure 7D).
DISCUSSION
It was previously not possible to study the genetic requirements
of HSC development in the conceptus in the absence of earlier
waves of EMP formation. Here we demonstrate that the forma-
tion of EMPs and HSCs can be uncoupled. The emergence of
both EMPs and HSCs requires Runx1 and its non-DNA binding
subunit CBFb. EMP formation in conceptuses lacking CBFb
could be rescued by the expression of a functional GFP/CBFb
fusion protein from Tek regulatory sequences (Miller et al.,
2002). HSCs could be rescued by the expression of GFP/CBFb
from Ly6a regulatory sequences. Thus EMPs and HSCs have
different temporal and/or spatial requirements for CBFb. Ly6a-
GFP/Cbfb-expressing endothelial cells in the yolk sac are not
yet present at the time EMPs emerge, and therefore CBFb is
required before the onset of Ly6a expression in the yolk sac for
EMP formation. On the other hand, Ly6a-GFP/Cbfb expression
in the dorsal aorta and vitelline and umbilical vasculature
precedes the emergence of HSCs, and Ly6a-GFP/Cbfb could.
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Figure 5. Expression of the Tek-GFP/Cbfb
and Ly6a-GFP/Cbfb Transgenes in 8.5–9.5
dpc Conceptuses Analyzed by Confocal
Microscopy
(A) Whole-mount immunofluorescence of a 7s Tek-
GFP/Cbfb conceptus using antibodies recog-
nizing CD31 and GFP (103). Scale bars = 250 mm.
Figure represents theMAX of six consecutive 3 mm
z sections for CD31 andGFP. DA, dorsal aorta; YS,
yolk sac; Al, allantois; Pl, placenta; H, heart.
(B) An 11s Ly6a-GFP/Cbfb conceptus, analyzed as
described in (A).
(C) A 16s Tek-GFP/Cbfb conceptus reconstructed
as the standard deviation (STD) of 13 consecutive
1.3 mm z sections for CD31, and the sum for GFP
(103). Scale bars = 250 mm.
(D) A 16s Ly6a-GFP/Cbfb conceptus, analyzed as
described in (C). Expression is observed in endo-
thelial cells in the caudal aspect of the dorsal
aortae, placenta, yolk sac (primarily caudal
region), vitelline artery (VA), vitelline vein (VV),
foregut (Fg), and hindgut (not shown). See also
Movie S1.
See also Figure S2 and Movie S2.
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HSC-Producing Hemogenic Endothelial Cellsrescue HSCs. That the rescue of HSCs by the Ly6a-GFP/Cbfb
transgene was only partial could reflect a slightly earlier require-
ment for CBFb in a subset of HSC precursors. Alternatively,
suboptimal expression levels of Cbfb expression could be
responsible. Previous studies showed that Runx1 haploinsuffi-
ciency differentially affected AGM HSC activity as compared to
that in yolk sac and placenta; thus, suboptimal expression levels
could underlie the selective failure of the Ly6a-GFP/Cbfb trans-
gene to rescue aorta, vitelline, and umbilical HSCs (Cai et al.,
2000; Robin et al., 2006).
Activation of an inactive, floxed Runx1 allele with Tek-Cre
restored both EMP and HSC formation; thus, the Tek regulatory
sequences should have been expressed sufficiently early in the
cells that give rise to EMPs and HSCs to rescue (Liakhovitskaia
et al., 2009). The most likely reason that Tek-GFP/Cbfb only
partially rescued EMPs, and failed to rescue HSC formation in
Cbfb/ conceptuses, is inadequate expression in endothelial
cells or in newly formed EMPs or HSCs. Partial EMP rescue byCell Stem Cell 9, 541–552,Tek-GFP/Cbfb could also reflect
a requirement for CBFb in cells in which
it is normally expressed and Tek is not,
such as the primitive streak (Bollerot
et al., 2005). Cbfb is expressed in the
posterior aspect of the primitive steak in
early and intermediate streak embryos,
while Runx1 expression initiates approxi-
mately 10 hr later in the area opaca (blood
islands). Because the Runx proteins are
reliant on CBFb for high-affinity DNA
binding, it would make sense for CBFb
to be present before Runx1 to ensure
that, once present, Runx1 is active. A
likely explanation for the failure of Tek-
GFP/Cbfb to rescue HSCs is that, unlikeRunx1, sustained CBFb expression may be required in HSCs.
In fact, preliminary data indicate that the number of HSCs in
mice in which CBFb is deleted in the fetal liver with Vav1-Cre is
decreased at least 25-fold (not shown), greater than the approx-
imate 4-fold decrease observed upon Runx1 deletion with Vav1-
Cre (Cai et al., 2011). The Ly6a-driven transgene, in contrast,
provided sustained expression of GFP/CBFb in fetal liver
HSCs. We point out that although low levels of cell surface Tek
are present on fetal liver HSCs (Hsu et al., 2000), this does not
necessarily mean that expression from a Tek-driven transgene
would supply adequate levels of CBFb to rescue HSC formation
or function.
Ly6a encodes a glycoprotein-I-linked cell-surface glycopro-
tein Sca1, which is a marker of stem/progenitor populations in
multiple organs (Holmes and Stanford, 2007). There are two
mouse strain-specific Ly6a alleles, only one of which is
expressed in all HSCs (Spangrude and Brooks, 1993). Despite
early work on Ly6a expression (DNaseI hypersensitivity) in theDecember 2, 2011 ª2011 Elsevier Inc. 547
Figure 6. Expression of the Tek-GFP/Cbfb
and Ly6a-GFP/Cbfb Transgenes in 10.5
dpc Conceptuses
(A) Whole-mount immunofluorescence of a 36s
Tek-GFP/Cbfb specimen using antibodies recog-
nizing CD31 and GFP (53). Scale bars = 500 mm.
View represents average of 14 10 mm z sections.
DA, dorsal aorta; UA, umbilical artery; VA, vitelline
artery; Fl, fetal liver.
(B) A 38s Ly6a-GFP/Cbfb specimen, analyzed as
described in (A). The Ly6a-GFP/Cbfb transgene is
also highly expressed in the tail. MT, Mullerian
tubules; HG, hindgut. See also Movie S3.
(C) Yolk sac from the Tek-GFP/Cbfb fetus shown
in (A) (53). View represents sum of 32 9.7 mm z
sections. Asterisk shows area of expression in the
yolk sac vascular plexus. Scale bars = 500 mm.
(D) Yolk sac from the Ly6a-GFP/Cbfb fetus shown
in (B), analyzed as described in (C). Arrows show
expression in large vitelline vessels.
(E) Umbilical artery from the Tek-GFP/Cbfb fetus
shown in (A) (203). View represents sum of six
0.38 mm z sections. Scale bars = 100 mm.
(F) Umbilical artery from the Ly6a-GFP/Cbfb fetus
shown in (B) (203), analyzed as described in (E).
(G) Intra-arterial hematopoietic cluster from the
umbilical artery of a Tek-GFP/Cbfb fetus (203).
(H) Intra-arterial hematopoietic cluster from the
umbilical artery of aLy6a-GFP/Cbfb fetus, as in (G).
See also Figures S3 and S5.
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HSC-Producing Hemogenic Endothelial CellsFDCP1multipotent progenitor and other hematopoietic cell lines
(Sinclair and Dzierzak, 1993), relatively little is known about the
regulation of Ly6a expression in endothelial cells, and nothing
is known at the transcriptional level. However, two mutant
mouse models showed decreased numbers of Ly6a-GFP-
expressing aortic endothelial cells. Embryos haploinsufficient
for Gata2 (HSC numbers were reduced) showed a 10-fold
decrease in GFP+ aortic endothelial cells (Ling et al., 2004),
and conceptuses deficient for Jagged1, a ligand for Notch,
had a 2-fold decrease (Robert-Moreno et al., 2008). Ly6a is regu-
lated in HSCs by interferon a signaling through STAT1 (Essers
et al., 2009); thus, signaling through JAK-STAT is a possible548 Cell Stem Cell 9, 541–552, December 2, 2011 ª2011 Elsevier Inc.mechanism for activating Ly6a expres-
sion in endothelium. We showed that
Ly6a expression is not, however, depen-
dent on Runx1-CBFb. A recent ChIP-
Seq analysis of multiple transcription
factors involved in hematopoietic devel-
opment (Tal1, Lyl1, Lmo2, Gata2,
Runx1, and Pu.1) found that the Ly6a
gene was occupied only by Pu.1 in
a hematopoietic progenitor cell line (Wil-
son et al., 2010). Although EMP cell lines
are fairly far removed from endothelium,
the indication that Ly6a is not a direct
Runx1 target is consistent with our obser-
vation that Ly6a expression in endothe-
lium is unaffected by CBFb deficiency.
Although expression of Ly6a in HSCs is
strain-specific, and a human equivalentdoes not exist, it would nevertheless be interesting to identify
the signals that activate expression of the mouse transgene in
the subset of endothelial cells that give rise to HSCs, as these
may provide clues as to how HSCs, as opposed to EMPs, are
specified. A comparison of gene expression profiles between
Ly6a-GFP+ and Ly6a-GFP endothelium might reveal other
markers that could be used to follow the development of the
comparable endothelium in human embryos and ESC cultures.
Most importantly, our data imply that there is a discrete endo-
thelial population in the mouse conceptus that gives rise to
HSCs, and that the murine Ly6a regulatory sequences are active
in these endothelial cells. Importantly, and quite unexpectedly,
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Figure 7. Ly6a Transgene Expression Marks a Subset of CD144+, ESAM+, CD105+, Tek+, Flk1+, and c-Kit+ Cells
(A) Live (DAPI) cells from the 10.5 dpc A+U+V were gated for GFP/CBFb in the plot furthest to the left, and GFP/CBFb+ cells are shown as red dots in this and all
other plots.
(B) Live cells are gated for CD31 and c-Kit expression and divided into endothelial cells (CD31+ c-Kit) and hematopoietic cells (CD31+ c-Kit+). Each population in
turn is analyzed for ESAM and CD144 expression, and all ESAM+ cells for CD144 and GFP/CBFb expression. Black numbers represent the percentage of all cells
in a particular gate, while red numbers represent percentages of GFP/CBFb+ cells in that gate.
(C) Analysis of CD105+, Tek+, and Flk1+ populations, gated as described in (A) and (B).
(D) Diagram illustrating that Ly6a-GFP expression marks the HSC-producing population of Runx1+ hemogenic endothelium.
See also Figure S4.
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Cell Stem Cell
HSC-Producing Hemogenic Endothelial CellsEMPs do not emerge if CBFb expression is restricted to Ly6a-ex-
pressing cells, indicating that the Ly6a-driven transgene is not
active in the hemogenic endothelium that gives rise to EMPs at
the time Runx1-CBFb is required. This interpretation is entirely
consistent with knownmarkers on EMPs and HSCs in themurine
conceptus. EMPs in the yolk sac are cell surface Sca1 (Huang
and Auerbach, 1993), while HSCs in the Ly6a-GFP AGM region
and placenta are in the GFP+ population (de Bruijn et al., 2002;
Ottersbach and Dzierzak, 2005). This has important implications
for ongoing efforts to produce HSCs ex vivo, from ESCs/iPSCs
and fibroblasts. Many investigators have generated EMPs and
lymphoid progenitors from these cell sources, but no functional
HSCs havebeenproducedwithout introducing geneticmodifica-
tions (Cho et al., 1999; Irion et al., 2010; Lengerke and Daley,
2010; Schmitt et al., 2004; Szabo et al., 2010). EMP formation
proceeds through an endothelial intermediate in ESC cultures
(Eilken et al., 2009; Lancrin et al., 2009), and presumably HSC
formation will as well. It would therefore be useful to follow the
generation of Ly6a-GFP+ endothelial cells in vitro when opti-
mizing conditions for HSC production.
EXPERIMENTAL PROCEDURES
Generation of Ly6a-GFP/Cbfb Transgenes
We generated Ly6a-GFP/Cbfb mice by inserting a cDNA coding for a GFP/
CBFb fusion protein into the Ly6a promoter/enhancer sequences. We intro-
duced silent mutations into the cDNA for GFP/CBFb (Adja et al., 1998) (a gift
from Paul Liu) to eliminate the SalI, XhoI, BglII, XhoI, and HindIII sites in order
to facilitate cloning. An artificial intron and poly-A signal was added to the 30
end of the coding region. The GFP/CBFb insert was amplified by PCR to intro-
duce ClaI sites at both ends, and then inserted into the ClaI site of pPOLYIII-
Ly6A14 (Ma et al., 2002a). The insert was flanked by 4 kb of upstream and
10 kb of downstream genomic sequences containing Ly6a regulatory
elements. The transgene was excised from the vector by BamHI and injected
into fertilized oocytes from C57BL/6 3 129S1/SVImJ F1 mice by the Brigham
and Women’s transgenic facility. Six independent founders were identified,
and three were further characterized. Tek-GFP/Cbfb and Cbfb+/
(Cbfbtm1Spe/+) mice were described previously (Miller et al., 2002; Wang
et al., 1996b).
PCR Genotyping Protocol and Primers
Animals were genotyped by PCR using tail DNA from adults, and yolk sac snips
or limb buds from conceptuses. The Tek-GFP/Cbfb transgene was detected
by the following primers: Tek-PF263: 50AGCGGGAAGTCGCAAAGTTGTG;
and GFP-R138: 50CTTCAGGGTCAGCTTGCCGTAG. The Ly6a-GFP/Cbfb
transgene was detected by the following: Ly6A-PF55: 50AGAACTTGCCAC
TGTGCCTGC; and GFP-R138: 50CTTCAGGGTCAGCTTGCCGTAG. Cbfb+/
was detected by three primers: CBFbex5R: 50CTCTCACCTCCATTTCCTC
CCG; CBFbex5F: 50TATTTCATGTACCCTGACAGCAGG; and PGKP-R-475:
50ATGCTCCAGACTGCCTTGGG. The Cbfb deleted allele yields an 400 bp
band, and the wild-type Cbfb allele yields an110 bp band. All PCR reactions
were run using the following program: 5 min denaturation at 94C followed by
35 cycles of denaturation (30 s at 94C), annealing (30 s at 60C), and elonga-
tion (1 min 30 s at 72C).
Embryo and Mouse Generation
Conceptuses were generated from timed matings. Detection of the vaginal
plug is 0.5 dpc. Ly6a-GFP/Cbfb and Cbfb/;Ly6a-GFP/Cbfb conceptuses
were generated by crossing Cbfb+/ ;Tg males with Cbfb+/ females. The
same strategy was used to generate Cbfb/;Tek-GFP/Cbfb conceptuses.
Cell Preparation
Embryonic cells were prepared for flow cytometry and methylcellulose and
transplant assays asdescribed previously (Chen et al., 2009; North et al., 2002).550 Cell Stem Cell 9, 541–552, December 2, 2011 ª2011 Elsevier IncFlow Cytometry
We used PerCP-Cy5.5 anti-Sca1 (D7), eFluorb 450 lineage specific cocktail
[(anti-TER119 (TER119), anti-Gr-1 (RB6-8C5), anti-B220 (RA3-6B2), anti-
CD3 (17A2), and anti-Mac-1 (M1/70)], APC anti-CD48 (HM48-1), APC eFluor
780 anti-c-Kit (2B8) (eBioscience), and PE-Cy7 anti-CD150 (SLAM) (Bio-
Legend) to stain adult bone marrow. Fetal liver cell staining is as above except
for removal of eFluor 450 anti-Mac-1 from the lineage cocktail, and staining
with PE anti-Mac-1 (M1/70). Dead cells were excluded with DAPI (Molecular
Probes). To analyze peripheral blood engraftment we used PerCP-Cy5.5
anti-Gr-1 (RB6-8C5), APC anti-CD3ε (145-2C11), PE anti-CD19 (1D3),
PE-Cy7 anti-Mac-1 (M1/70) (BD PharMingen), V450 anti-CD45.2 (104)
(BD Horizon), and PE-Cy5 anti-CD45.1 (A20). Dead cells were excluded with
Fixable Viability Dye eFluor 780 (eBioscience). To examine HSC/endothelial
marker expression we used PE-Cy7-anti-CD31 (390), Alexa Fluor 647-
anti-CD144 (eBioBV13), PE-anti-CD105 (MJ7/18), PE-anti-Tie2 (TEK4)
(eBioscience), PE-anti-ESAM (1G8/ESAM), and PE-anti-Flk1 (89B3A5) (Bio-
Legend). Dead cells were excluded by DAPI staining. We analyzed cells on
an LSR II flow cytometer (BD Biosciences, San Jose CA), and analyzed data
with FlowJo (Tree Star, Ashland, OR). Cells were sorted on a FACSAria (BD
Biosciences).
Cell Culture
OP9 and OP9-DL4 cells were essentially used as described (Schmitt and
Zu´n˜iga-Pflu¨cker, 2006). For OP9-DL4 cultures, IL-7 was added at a final
concentration of 1 ng/ml, and Flt3 ligand, at 5 ng/ml. OP9 cultures included
IL-7 at a final concentration of 10 ng/ml. Stromal cells were plated 2 days
before initiation of culture at a concentration of 20,000 cells/ml in 96-well
plates. Cultures were examined after 7 days of culture by flow cytometry.
For in vitro limiting-dilution analysis, the progenitor frequency was calculated
using the method of maximum likelihood applied to Poisson distribution with
L-Calc software (StemCell Technologies).
Transplant Analyses
129S1/SvImJ 3 B6.SJL-Ptprca Pepcb/BoyJ F1 mice (CD45.1/CD45.2) were
subjected to a split dose of 900 cGy, 3 hr apart. Each recipient received 0.9
embryo equivalent of donor fetal liver, yolk sac, placenta, or AGM and arteries,
and 23 105 carrier spleen cells via tail vein injection. All donor fetuses were of
a mixed C57BL/6J and 129S1/SVImJ background and expressed CD45.2.
Spleen cells were prepared from B6.SJL-Ptprca Pepcb/BoyJ (CD45.1) mice.
We assessed donor engraftment of peripheral blood 16 weeks later.
Western Blot Analyses
Bone marrow was isolated and resuspended at 1 3 106 cells per ml in lysis
buffer (150 mMNaCl, 50 mM Tris [pH 8.0], 1% Nonidet P-40, 0.5% deoxycho-
late, 0.1% SDS, 0.2 mM EDTA, 2.0 mM EGTA plus 1 mg/ml pepstatin A, 1 mM
Pefablock, 2 mg/ml leupeptin, and 2 mg/ml aprotinin). Lysates equivalent to 23
105 cells were boiled in SDS loading buffer and resolved by SDS-PAGE
through 4%12%Bis-Tris gels (Invitrogen). Proteins were transferred to nitro-
cellulose, and the blot was probedwithmousemonoclonal antibodies to CBFb
(b141.4.1 + b141.2.2.5) and developed with ECL reagents (Pico kit, Pierce,
Rockford, IL).
Microscopy and Imaging
Imagesofdissected intactconceptuses inphosphate-bufferedsalinewerevisu-
alized using a Leica MZFIII stereomicroscope equipped with a Plan 1X
0.14(0.025–0.125) objective lens (Leica, Heerbrugg, Switzerland). A Color
Mosaic 11.2 camera and Spot Insight 4.0 acquisition software (Diagnostic
Instruments,SterlingHeights,MI)wereused tocapture images,whichwerepro-
cessed with Adobe Photoshop CS4 software (Adobe Systems, San Jose, CA).
Whole-mount immunohistochemistry was performed as described (Yoko-
mizo and Dzierzak, 2010; Yokomizo et al., 2011). Biotinylated rat anti-mouse
CD31 (MEC13.3, BD Biosciences) and rabbit anti-GFP polyclonal antibody
(MBL, Naka-ku Nagoya) were used with Cy-3-conjugated streptavidin (Jack-
son Immuno Research, West Grove, PA) and Alexa Fluor 647 goat anti-rabbit
IgG (Invitrogen). Specimens were analyzed with a Leica DM 6000 upright
confocal microscope with HCX PL FLUOTAR 5.0 3 0.15, NA 0.15/ HC PL
APO CS 10.0 3 0.4, NA 0.4 objectives using multitrack sequential mode..
Cell Stem Cell
HSC-Producing Hemogenic Endothelial CellsPinhole diameter was set at 1 Airy unit and steps were 1.3–9.7 mm per z
section.
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